Artiva Biotherapeutics, Inc. (ARTV)Healthcare | Biotechnology | San Diego, United States | NasdaqGM
11.09 USD
-0.85
(-7.119%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 11.14 +0.05 (0.451%) ⇧ (Aug. 28, 2026, 7:30 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 5:50 a.m. EDT
The investment case for Artiva Biotherapeutics is currently broken by a catastrophic multi-year price collapse and deteriorating fundamentals. The stock has lost over 70% of its value in just one year, a trajectory that signals the market has priced out the business entirely. Fundamentally, the company is bleeding cash with negative free cash flow and negative returns on equity, while holding minimal cash reserves against significant debt obligations. Although analysts maintain a 'strong buy' rating with lofty price targets, these valuations ignore the reality of a biotech firm burning through capital without proven commercial success. The options market confirms this pessimism, with traders aggressively buying protection via out-of-the-money puts. There is no dividend to cushion the blow, and the recent news of insider purchases appears negligible compared to the scale of the company's financial distress. Until the balance sheet stabilizes and a major clinical milestone is definitively cleared, this remains a high-risk speculative vehicle. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.295684 |
| AutoARIMA | 0.304865 |
| MSTL | 0.304937 |
| AutoTheta | 0.312357 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 26% |
| H-stat | 3.20 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.014 |
| Excess Kurtosis | 0.70 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 2.834 |
| Market Cap | 542,191,424 |
| Forward P/E | -4.25 |
| Beta | 2.18 |
| Website | https://www.artivabio.com |
As of Aug. 22, 2026, 5:50 a.m. EDT: Speculators are positioning for a continued grind lower rather than a rebound. While there is some open interest in out-of-the-money calls for February 2027, the overwhelming majority of option volume and open interest sits in out-of-the-money puts across all expirations. This heavy put positioning suggests traders are betting on further downside volatility, likely driven by concerns over the company's cash burn and the failure of recent trials to meet expectations despite positive headlines.
| Attribute | Value |
|---|---|
| 52 Week Change | 2.5889966 |
| Address1 | 5,505 Morehouse Drive |
| Address2 | Suite 100 |
| All Time High | 17.31 |
| All Time Low | 1.47 |
| Ask | 14.33 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 280,380 |
| Average Daily Volume3 Month | 480,968 |
| Average Volume | 480,968 |
| Average Volume10Days | 280,380 |
| Beta | 2.177 |
| Bid | 8.05 |
| Bid Size | 2 |
| Book Value | 7.122 |
| City | San Diego |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 11.09 |
| Current Ratio | 24.16 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 11.8 |
| Day Low | 11.11 |
| Debt To Equity | 2.834 |
| Display Name | Artiva Biotherapeutics |
| Earnings Timestamp End | 1,754,569,800 |
| Earnings Timestamp Start | 1,754,569,800 |
| Ebitda | -93,462,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -2.168 |
| Enterprise Value | 202,646,448 |
| Eps Current Year | -2.51 |
| Eps Forward | -2.608 |
| Eps Trailing Twelve Months | -3.23 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 10.3856 |
| Fifty Day Average Change | 0.70440006 |
| Fifty Day Average Change Percent | 0.067824684 |
| Fifty Two Week Change Percent | 258.89966 |
| Fifty Two Week High | 14.53 |
| Fifty Two Week High Change | -3.4399996 |
| Fifty Two Week High Change Percent | -0.23675153 |
| Fifty Two Week Low | 2.22 |
| Fifty Two Week Low Change | 8.87 |
| Fifty Two Week Low Change Percent | 3.9954953 |
| Fifty Two Week Range | 2.22 - 14.53 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,721,395,800,000 |
| Float Shares | 21,345,427 |
| Forward Eps | -2.608 |
| Forward P E | -4.2523007 |
| Free Cashflow | -44,431,500 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 115 |
| Fullday Change | -0.849999 |
| Fullday Change Percent | -7.11892 |
| Fullday Price | 11.14 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.14887999 |
| Held Percent Institutions | 0.84053004 |
| Implied Shares Outstanding | 48,890,121 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,024-07-19 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma. The company also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 targeting chimeric antigen receptor (CAR)-NK cell product candidate for the treatment of various solid tumors, such as breast, gastric and esophageal, and bladder cancers; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate for the treatment of hematological malignancies. Artiva Biotherapeutics, Inc. was incorporated in 2019 and is headquartered in San Diego, California. |
| Long Name | Artiva Biotherapeutics, Inc. |
| Market | us_market |
| Market Cap | 542,191,424 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_672643147 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -90,821,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 583,748,044 |
| Number Of Analyst Opinions | 5 |
| Open | 11.78 |
| Operating Cashflow | -75,232,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 858 267 4467 |
| Post Market Change | 0.05000019 |
| Post Market Change Percent | 0.45085835 |
| Post Market Price | 11.14 |
| Post Market Time | 1,787,959,804 |
| Previous Close | 11.94 |
| Price Eps Current Year | -4.418327 |
| Price Hint | 2 |
| Price To Book | 1.5571468 |
| Profit Margins | 0.0 |
| Quick Ratio | 24.061 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.849999 |
| Regular Market Change Percent | -7.11892 |
| Regular Market Day High | 11.8 |
| Regular Market Day Low | 11.01 |
| Regular Market Day Range | 11.01 - 11.8 |
| Regular Market Open | 11.78 |
| Regular Market Previous Close | 11.94 |
| Regular Market Price | 11.09 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 222,786 |
| Return On Assets | -0.22338 |
| Return On Equity | -0.36581 |
| Sand P52 Week Change | 0.20204377 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 48,890,121 |
| Shares Percent Shares Out | 0.0429 |
| Shares Short | 2,095,813 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 1,724,074 |
| Short Name | Artiva Biotherapeutics, Inc. |
| Short Percent Of Float | 0.061100002 |
| Short Ratio | 5.61 |
| Source Interval | 15 |
| State | CA |
| Symbol | ARTV |
| Target High Price | 41.0 |
| Target Low Price | 23.0 |
| Target Mean Price | 35.8 |
| Target Median Price | 40.0 |
| Total Cash | 349,393,984 |
| Total Cash Per Share | 7.147 |
| Total Debt | 9,849,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -3.23 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 7.2142 |
| Two Hundred Day Average Change | 3.8758001 |
| Two Hundred Day Average Change Percent | 0.537246 |
| Type Disp | Equity |
| Volume | 222,786 |
| Website | https://www.artivabio.com |
| Zip | 92,121 |